I've been looking at XLV lately and there's something worth paying attention to if you're into the healthcare industry ETF space. This fund has been around since late 1998 and it's basically the go-to option for getting broad exposure to healthcare stocks without overthinking individual picks.

What caught my eye first is the cost structure. At 0.08% expense ratio, this thing is dirt cheap compared to alternatives. Over decades of investing, that kind of efficiency really compounds. The fund sits on over $34 billion in assets, so it's clearly the heavyweight in matching the healthcare industry ETF performance. You're getting exposure to pharma, biotech, medical equipment, healthcare services, and related tech.

Looking at the actual holdings, the top three names are Eli Lilly, Johnson & Johnson, and UnitedHealth Group, with Lilly making up about 12.4% of the portfolio. The top 10 holdings represent roughly 56% of assets, so there's decent concentration but still enough diversification with around 61 total positions to smooth out company-specific risk.

Performance-wise, it's been a bit choppy. The fund was down roughly 6% over the trailing year from mid-2025, but that's pretty typical for healthcare sector plays. What's interesting is the risk profile - with a beta of 0.63, this healthcare industry ETF actually moves less than the broader market, making it a medium-risk option. The 52-week range was between $128 and $157, so there's been meaningful volatility despite the lower beta.

The dividend yield sits around 1.72%, which isn't amazing but reasonable for a sector fund. And it carries a Zacks Rank of 1, which basically means the analysts think it's a solid pick.

If you're comparing alternatives, there's Vanguard's healthcare ETF at 0.09% expense ratio with $15 billion in assets, or the iShares Global Healthcare ETF if you want international exposure. But honestly, if you just want broad healthcare industry ETF exposure with minimal fees, XLV is hard to beat. The combination of low costs, massive asset base, and solid diversification makes it a no-brainer for long-term investors.